NasdaqGS:ARQTBiotechs
Arcutis Biotherapeutics (ARQT) Is Up 14.4% After Narrowing Losses in Q2 Earnings Report Has Sentiment Shifted?
Arcutis Biotherapeutics reported second quarter 2025 earnings showing revenue of US$81.5 million and a net loss of US$15.89 million, both improved from the prior year.
Results highlight substantial operational progress, with strong revenue growth and a significant reduction in loss per share compared to the same period last year.
We'll examine how these operational improvements and narrowing losses reshape Arcutis Biotherapeutics' longer-term investment outlook.
AI is about to change...